このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Cosnine マネジメント

マネジメント基準チェック /04

現在、CEO に関する十分な情報がありません。

主要情報

Keon-Joon Ahn

最高経営責任者

n/a

報酬総額

CEO給与比率	n/a
CEO在任期間	no data
CEOの所有権	n/a
経営陣の平均在職期間	データなし
取締役会の平均在任期間	データなし

経営陣の近況

Recent updates

Is Cosnine (KOSDAQ:082660) Using Debt In A Risky Way?

Mar 22

CEO（最高経営責任者

Keon-Joon Ahn (59 yo)

no data

在職期間

Mr. Keon-Joon Ahn serves as Chief Executive Officer and Director of Cosnine Co., Ltd (formerly known as 9complex Co., Ltd).

Cosnine マネジメント

マネジメント基準チェック /04

主要情報

経営陣の近況

No independent directors

No independent directors

No independent directors

Recent updates

Is Cosnine (KOSDAQ:082660) Using Debt In A Risky Way?

Cosnine Co., Ltd. announced that it has received KRW 4 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment Arm

No independent directors

No independent directors

No independent directors

Full year 2021 earnings released: ₩242 loss per share (vs ₩443 loss in FY 2020)

Third quarter 2021 earnings released: ₩9.61 loss per share (vs ₩39.00 loss in 3Q 2020)

Cosnine Co., Ltd. announced that it has received KRW 6.0116 billion in funding from Icure Pharmaceutical Incorporation

Cosnine Co., Ltd. announced that it expects to receive KRW 6.0116 billion in funding

New 90-day low: ₩1,460

Cosnine Co., Ltd. announced that it has received KRW 4 billion in funding from Icure Pharmaceutical Incorporation

Cosnine Co., Ltd. announced that it expects to receive KRW 4 billion in funding from Icure Pharmaceutical Incorporation and another investor

Cosnine Co., Ltd. announced that it has received KRW 4.99954 billion in funding

Cosnine Co., Ltd. announced that it expects to receive KRW 999.99879 million in funding

New 90-day high: ₩1,630

Cosnine Co., Ltd. announced that it expects to receive KRW 4.99954 billion in funding

Cosnine Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99985 million.

Cosnine Co., Ltd. announced that it expects to receive KRW 2 billion in funding from Sangsangin Savings Bank, Investment Arm

New 90-day low - ₩1,220

Cosnine Co., Ltd. announced that it expects to receive KRW 2 billion in funding

CEO（最高経営責任者

在職期間

Cosnine マネジメント

マネジメント 基準チェック /04

主要情報

経営陣の近況

No independent directors

No independent directors

No independent directors

Recent updates

Is Cosnine (KOSDAQ:082660) Using Debt In A Risky Way?

Cosnine Co., Ltd. announced that it has received KRW 4 billion in funding from Sangsangin Savings Bank, Investment Arm, Sangsangin Plus Savings Bank, Investment Arm

No independent directors

No independent directors

No independent directors

Full year 2021 earnings released: ₩242 loss per share (vs ₩443 loss in FY 2020)

Third quarter 2021 earnings released: ₩9.61 loss per share (vs ₩39.00 loss in 3Q 2020)

Cosnine Co., Ltd. announced that it has received KRW 6.0116 billion in funding from Icure Pharmaceutical Incorporation

Cosnine Co., Ltd. announced that it expects to receive KRW 6.0116 billion in funding

New 90-day low: ₩1,460

Cosnine Co., Ltd. announced that it has received KRW 4 billion in funding from Icure Pharmaceutical Incorporation

Cosnine Co., Ltd. announced that it expects to receive KRW 4 billion in funding from Icure Pharmaceutical Incorporation and another investor

Cosnine Co., Ltd. announced that it has received KRW 4.99954 billion in funding

Cosnine Co., Ltd. announced that it expects to receive KRW 999.99879 million in funding

New 90-day high: ₩1,630

Cosnine Co., Ltd. announced that it expects to receive KRW 4.99954 billion in funding

Cosnine Co., Ltd. has completed a Follow-on Equity Offering in the amount of KRW 999.99985 million.

Cosnine Co., Ltd. announced that it expects to receive KRW 2 billion in funding from Sangsangin Savings Bank, Investment Arm

New 90-day low - ₩1,220

Cosnine Co., Ltd. announced that it expects to receive KRW 2 billion in funding

CEO（最高経営責任者

在職期間

マネジメント基準チェック /04